Twenty-four Month Outcomes in the Collaborative Ocular Tuberculosis Study (COTS)-1: Defining the "Cure" in Ocular Tuberculosis
Overview
Authors
Affiliations
: To report the clinical findings, anatomical features, and treatment outcomes in subjects with ocular tuberculosis (OTB) at 24 months in the Collaborative Ocular Tuberculosis Study (COTS)-1.: Of the 945 subjects included in COTS-1, those who completed a 24-month follow-up after completion of treatment were included. The main outcome measure was a number of patients with treatment failure (TF).: 228 subjects (120 males; mean age of 42.82 ± 14.73 years) were included. Most common phenotype of uveitis was posterior ( = 81; 35.53%), and panuveitis ( = 76; 33.33%). Fifty-two patients (22.81%) had TF. On univariable analysis, odds of high TF was observed with bilaterality (OR: 3.46, = .003), vitreous haze (OR: 2.14, = .018), and use of immunosuppressive therapies (OR: 5.45, = .003). However, only bilaterality was significant in the multiple regression model (OR: 2.84; = .02).: Majority of subjects (>75%) achieved cure in the COTS-1 at 24-month follow-up. The concept of "cure" may be a valuable clinical endpoint in trials for OTB.
Xu H, Xu M, Chen F, Chen H, Du W, Yu J BMC Ophthalmol. 2025; 25(1):7.
PMID: 39762811 PMC: 11702118. DOI: 10.1186/s12886-025-03843-0.
Long-term follow-up after treatment of tubercular uveitis: case series and review of the literature.
Putera I, van Daele P, Ten Berge J, Dik W, La Distia Nora R, van Hagen P Front Ophthalmol (Lausanne). 2024; 3:1270948.
PMID: 38983011 PMC: 11182287. DOI: 10.3389/fopht.2023.1270948.
An excursion into ocular tuberculosis.
Yen D, Betzler B, Neo E, Lai S, Arora A, Agrawal R Saudi J Ophthalmol. 2023; 36(4):365-373.
PMID: 36618567 PMC: 9811922. DOI: 10.4103/sjopt.sjopt_195_21.
Kalra G, Agarwal A, Marchese A, Agrawal R, Bansal R, Gupta V Sci Rep. 2022; 12(1):5392.
PMID: 35354885 PMC: 8967847. DOI: 10.1038/s41598-022-09338-y.
Treatment Outcome of Tubercular Uveitis in a High TB and HIV Setting: A Prospective Cohort Study.
Alli H, Ally N, Mayet I, Joseph L, Omar S, Madhi S Clin Ophthalmol. 2022; 15:4839-4846.
PMID: 35002219 PMC: 8722693. DOI: 10.2147/OPTH.S342268.